Healthy Skepticism Library item: 5285
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Langton PE, Hankey GJ, Eikelboom JW.
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.
Med J Aust 2004 Nov 15; 181:(10):524-5
http://www.mja.com.au/public/issues/181_10_151104/lan10728_fm.html
Keywords:
Cardiovascular Diseases/chemically induced*
Cyclooxygenase Inhibitors/adverse effects*
Cyclooxygenase Inhibitors/pharmacology
Cyclooxygenase Inhibitors/therapeutic use
Humans
Lactones/adverse effects*
Lactones/pharmacology
Lactones/therapeutic use
Product Surveillance, Postmarketing
Risk Assessment
Sulfones/adverse effects*
Sulfones/pharmacology
Sulfones/therapeutic use
